DEEPA ABHILASH: Open Payments
NPI 1831718972 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,272 in 53 payments from 11 companies in 2025. Trend: 2023 $1,200 · 2024 $1,204 · 2025 $1,272
Food & beverage: $1,272
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $292 |
| E.R. Squibb & Sons, L.L.C. | 6 | $220 |
| ABBVIE INC. | 14 | $208 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Alkermes, Inc. | 4 | $92 |
| Lundbeck LLC | 4 | $89 |
| Neurocrine BioSciences, Inc. | 3 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Janssen Pharmaceuticals, Inc | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
Products named: COBENFY, VRAYLAR, REXULTI, ABILIFY MAINTENA, Auvelity, ARISTADA, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
